Press "Enter" to skip to content

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®

Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor (RAASi) therapy. Veltassa® demonstrated a statistically significant difference versus placebo for the primary endpoint to serum potassium levels in a high risk population…


– 출처 : https://www.newswire.co.kr/newsRead.php?no=936949&sourceType=rss